Gene therapy for malignant mesothelioma: beyond the infant years

Robbert Van Der Most, Bruce Robinson, Delia Nelson

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)


Mesothelioma may be particularly well suited for gene therapy treatment owing to its accessibility, allowing both intrapleural and intratumoral gene delivery. At least four gene therapy trials have been carried out in mesothelioma patients, using different vector systems ( adenovirus, vaccinia virus, irradiated tumor cells), and different transgenes ( herpes simplex virus thymidine kinase (HSVtk) combined with ganciclovir, IL-2, IFN-b). Although small in scale, these trials have given an inkling of hope for therapeutic efficacy. However, it is clear that gene therapy protocols need to be optimized further. This paper will review progress made in (i) vector development, (ii) defining optimal transgenes, and (iii) gene delivery. Adenoviruses are the most commonly used vectors for gene therapy, and are continuously being improved. With respect to the nature of the transgenes, five categories can be distinguished: (i) 'suicide' or sensitivity genes (e.g., HSVtk), (ii) cytokines and other immune modulators, ( iii) replacements for mutant tumor suppressor genes (e.g., p53), (iv) antiangiogenic proteins and (v) tumor antigens. It seems clear that expression of a single transgene is unlikely to be sufficient to eradicate a tumor, such as mesothelioma, that is diagnosed late in disease progression. Hence, multimodality therapy, including conventional therapy (chemo- and radiotherapy, surgery) with one or more transgenes has a higher chance of success.
Original languageEnglish
Pages (from-to)897-904
JournalCancer Gene Therapy
Publication statusPublished - 2006


Dive into the research topics of 'Gene therapy for malignant mesothelioma: beyond the infant years'. Together they form a unique fingerprint.

Cite this